Members of the Lithuanian biotechnology association participated in the exhibition Arab Health 2023, held in Dubai, United Arab Emirates on January 29 – February 2.
The Arab Health 2023 is international exhibition of health care and medical technologies held in Dubai. Exhibition attracted as many as 2,828 exhibitors from 70 countries worldwide. The event attracted more than 120,000 visitors.
The Lithuanian biotechnology sector participated in the international exhibition Arab Health 2023 for the first time. At the national Lithuanian stand, organized by the Lithuanian biotechnology association, were presented representatives from 9 biotechnology, medical technology and life sciences companies: UAB Caszyme, UAB Ligence, UAB Vaizduotė, UAB Telemedicina, UAB Medical technologies, Inovatyvios diagnostikos centras, UAB Placenta, UAB Psylink, UAB Emplastrum.
On January 30, the Lithuanian biotechnology association and the Innovation agency and the representatives of Lithuanian companies and startups met the Lithuanian Ambassador to the United Arab Emirates (UAE) Ramūnas Davidonis and commercial attache Gabriele Niekytė in the Arab Health 2023.
Representatives of Lithuania with Ambassador R. Davidonis discussed the environment of business development and creation in the UAE, methods and possibilities of finding partners and the strategic goals of the state. The Ambassador welcomes the growing interest of the life and biotech sector in the opportunities in the UAE and the countries of the region.
During the visit of Ambassador R. Davidonis, were also discussed the possibilities of Lithuania’s investment potential and business interests, opportunities for development and partner search in the UAE and the region with the UAE investment and medical technology company “Mubadala Health” and the Dubai Science Park.
The participation of Lithuanian companies in these events was implemented according to the according to the project “Search for new foreign markets of the Lithuanian Biotechnology Association” implemented in accordance with the 2014-2020 European Union funds investment action program measures 03.2.1-LVPA-K-801 “New opportunities LT” no. 06.